Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 205.91

+1.7%

1:38 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Machaon who wrote (20950)	5/16/1998 10:51:00 PM
From: Henry Niman	Read Replies (1) of 32384

Robert, the Barron's article reiterates some of the points made by several brokerage firms. The ENMD phenomena has focused investor attention on Biotechs in general and cancer biotechs in particular. The sector has been depressed and is very cheap right now. There is no magic cancer cure, but the sector may be ready to take off. SUGN and LGND are leaders in signal transduction and LGND has Panretin and Targretin in advanced clinical trials. The interview was with Lehman's Butler (he gives LGND his highest rating). The LGND/SRGN deal was also mentioned (Lehman did the M&Q for SRGN). I think that the article provides and excellent entry for the current ASCO conference. LGND will be all over the place. 6 abstracts on Targretin, Panretin, and ALRT1550 and the place will be buzzing about LLY's Evista due to impressive data and focus on cancer prevention (breast and prostate). Opportunity for several news items and LGND can fan the flames with NDA filing and ONTAK positive rec. Flying platform looking more and more like launch pad.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next